The extent and determinants of changes in CYP2D6 and CYP1A2 activities with therapeutic doses of sertraline

Journal of Clinical Psychopharmacology

Volumn 18, Issue 1, 1998, Pages 55-61

  Özdemir, Vural ^a,b   Naranjo, Claudio A ^a,b   Herrmann, Nathan ^a   Shulman, Richard W ^a   Sellers, Edward M ^a,b   Reed, Ken ^a   Kalow, Werner ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; CAFFEINE; CARBAMAZEPINE; CODEINE; CONJUGATED ESTROGEN; CONTAC COUGH CAPS DM; CYTOCHROME P450 ISOENZYME; DEBRISOQUINE 4 HYDROXYLASE; DEXTROMETHORPHAN; DICLOFENAC; FOSINOPRIL; FUROSEMIDE; INDOMETACIN; ISOSORBIDE DINITRATE; LEVOTHYROXINE; LITHIUM; LORAZEPAM; METOPROLOL; MISOPROSTOL; NORSERTRALINE; OMEPRAZOLE; PARACETAMOL; PHENACETIN O DEETHYLASE; PHENYTOIN; POTASSIUM; SERTRALINE; SIMVASTATIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; WAKE UPS;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHENOTYPE; PRIORITY JOURNAL;

1-NAPHTHYLAMINE; ADULT; AGED; AGED, 80 AND OVER; CAFFEINE; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; DEXTROMETHORPHAN; FEMALE; HUMANS; ISOENZYMES; MALE; MIDDLE AGED; SEROTONIN UPTAKE INHIBITORS; SERTRALINE;

EID: 0031974298     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199802000-00009     Document Type: Article

References (33)

1. Kasper S, Heiden A. Do SSRIs differ in their antidepressant efficacy. Hum Psychopharmacol 1995;10:S163-S172.
2. Eichelbaum M, Gross AS. The genetic polymorphism of debrisoquine/sparteine metabolism - clinical aspects. Pharmacol Ther 1990;46:377-94.
3. von Moltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RI. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol 1995;15:125-31.
4. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992;34:262-5.
5. Otton SV, Wu D, Joffe RT, Cheung SW, Sellers EM. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 1993;53:401-9.
6. Preskorn SH, Alderman J, Chung M, Harrison W, Messig M, Harris S. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol 1994;14:90-8.
7. Preskorn SH, Lane RM. Sertraline 50 mg daily: the optimal dose in the treatment of depression. Int Clin Psychopharmacol 1995; 10:129-41.
8. Kurtz DL, Bergstrom RF, Goldberg MJ, Cerimele BJ. The effect of sertraline on the pharmacokinetics of desipramine and imipramine. Clin Pharmacol Ther 1997;62:145-56.
9. Zussman BD, Davie CC, Fowles SE, Kumar R, Lang U, Wargenau M, Sourgens H. Sertraline, like other SSRIs, is a significant inhibitor of desipramine metabolism in vivo [abstract]. Br J Clin Pharmacol 1995;39:550P-551P.
10. Riesenman C, Ereshefsky L, Lam YWF. In vivo relationship of selective serotonin reuptake inhibitor plasma concentration with CYP2D6 inhibition [abstract]. Psychopharmacol Bull 1996;32:503.
11. Sproule BA, Otton SV, Cheung SW, Zhong XH, Romach MK, Sellers EM. CYP2D6 inhibition in patients treated with sertraline. J Clin Psychopharmacol 1997;17:102-6.
12. Butler MA, Iwasaki M, Guengerich FP, Kadlubar FF. Human cytochrome P-450PA (P-450IA2), the phenacetin-O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and JV-oxidation of carcinogenic arylamines. Proc Natl Acad Sci USA 1989;86:7696-700.
13. Brøsen K. Are pharmacokinetic drug interactions with the SSRIs an issue? Int Clin Psychopharmacol 1996;11[suppl 1]:23-7.
14. von Moltke LL, Greenblatt DJ, Duan SX, Schmider J, Kudchadker L, Fogelman SM, Harmatz JS, Shader RI. Phenacetin O-deethylation by human liver microsomes in vitro: inhibition by chemical probes, SSRI antidepressants, nefazodone and venlafaxine. Psychopharmacology (Berl) 1996;128:39S-407.
15. Ware JE, Sherboume D. The MOS 36-item short-form health survey (SF-36). Conceptual framework and item selection. Med Care 1992;30:473-83.
16. Tang B-K, Kalow W. Assays for CYP1A2 by testing in vivo metabolism of caffeine in humans. Methods Enzymol 1996;272: 124-31.
17. Kalow W, Tang B-K. The use of caffeine for enzyme assays: a critical appraisal. Clin Pharmacol Ther 1993;53:503-14.
18. Rogowsky D, Marr M. Long G, Moore C. Determination of sertraline and desmethylsertraline in human serum using copolymeric bonded-phase extraction, liquid chromatography and gas chromatography-mass spectrometry. J Chromatogr B Biomed Appl 1994;655:138-41.
19. Rasmussen BB, Maenpaa J, Pelkonen O, Loft S, Poulsen HE, Lykkesfeldt J, Brøsen K. Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. Br J Clin Pharmacol 1995;39: 151-9.
20. Rosner B. Fundamentals of biostatistics. 3rd ed. Belmont, CA: Wadsworth Publishing Company, 1990:273-4.
21. Kalow W, Tang B-K. Caffeine as a metabolic probe: exploration of the enzyme-inducing effect of cigarette smoking. Clin Pharmacol Ther 1991:49:44-8.
22. Özdemir V, Naranjo CA, Shulman RW, Herrmann N, Sellers EM, Reed K, Kalow W. Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo. J Clin Psychopharmacol 1998 (in press).
23. Gupta RN, Dziurdzy SA. Therapeutic monitoring of sertraline. Clin Chem 1994;40:498-9.
24. Grimsley SR, Jann MW. Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors. Clin Pharm 1992;11: 930-57.
25. Bock KW, Schrenk D, Forster A, Griese E-U, Mörike K, Brockmeier D, Eichelbaum M. The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics 1994;4:209-18.
26. Kalow W, Tang B-K. Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities. Clin Pharmacol Ther 1991;50:508-19.
27. Dayer P, Desmeules J, Leemann T, Striberni R. Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P450 dbl/bufl). Biochem Biophys Res Commun 1988;152:411-6.
28. Leemann T, Transon C, Dayer P. Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4′-hydroxylation in human liver. Life Sci 1993; 52:29-34.
29. Evans WE, Relling MV, Petros WP, Meyer WH, Mirro J, Crom WR. Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin-oxidation and N-acetylation phenotypes in children. Clin Pharmacol Ther 1989;45:568-73.
30. Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Brøsen K. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 1996;51:73-8.
31. Özdemir V, Naranjo CA, Herrmann N, Reed K, Sellers EM, Kalow W. Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P450 2D6 inhibition in vivo. Clin Pharmacol Ther 1997;62:334-47.
32. Jeppesen U, Loft S, Poulsen HE, Brøsen K. A fluvoxamine-caffeine interaction study. Pharmacogenetics 1996;6:213-22.
33. Hamelin BA, Turgeon J, Vallée F, Bélanger P-M, Paquet F, LeBel M. The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. Clin Pharmacol Ther 1996;60: 512-21.